Jeanette Saskowski
Last active: 3/4/2019


Lab Manager

Dugan Lab




The following timeline graph is generated from all co-authored publications.

Featured publications are shown below:

  1. Panobinostat sensitizes cyclin E high, homologous recombination-proficient ovarian cancer to olaparib. Wilson AJ, Sarfo-Kantanka K, Barrack T, Steck A, Saskowski J, Crispens MA, Khabele D (2016) Gynecol Oncol 143(1): 143-151
    › Primary publication · 27444036 (PubMed) · PMC5031537 (PubMed Central)
  2. Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer. Wilson AJ, Saskowski J, Barham W, Khabele D, Yull F (2015) Mol Cancer : 192
    › Primary publication · 26552746 (PubMed) · PMC4640396 (PubMed Central)
  3. Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer. Wilson AJ, Saskowski J, Barham W, Yull F, Khabele D (2015) J Ovarian Res : 46
    › Primary publication · 26215403 (PubMed) · PMC4517540 (PubMed Central)
  4. Aberrant over-expression of COX-1 intersects multiple pro-tumorigenic pathways in high-grade serous ovarian cancer. Wilson AJ, Fadare O, Beeghly-Fadiel A, Son DS, Liu Q, Zhao S, Saskowski J, Uddin MJ, Daniel C, Crews B, Lehmann BD, Pietenpol JA, Crispens MA, Marnett LJ, Khabele D (2015) Oncotarget 6(25): 21353-68
    › Primary publication · 25972361 (PubMed) · PMC4673270 (PubMed Central)
  5. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Konstantinopoulos PA, Wilson AJ, Saskowski J, Wass E, Khabele D (2014) Gynecol Oncol 133(3): 599-606
    › Primary publication · 24631446 (PubMed) · PMC4347923 (PubMed Central)
  6. Tracking NF-κB activity in tumor cells during ovarian cancer progression in a syngeneic mouse model. Wilson AJ, Barham W, Saskowski J, Tikhomirov O, Chen L, Lee HJ, Yull F, Khabele D (2013) J Ovarian Res 6(1): 63
    › Primary publication · 24020521 (PubMed) · PMC3846584 (PubMed Central)
  7. TR3 modulates platinum resistance in ovarian cancer. Wilson AJ, Liu AY, Roland J, Adebayo OB, Fletcher SA, Slaughter JC, Saskowski J, Crispens MA, Jones HW, James S, Fadare O, Khabele D (2013) Cancer Res 73(15): 4758-69
    › Primary publication · 23720056 (PubMed) · PMC3944084 (PubMed Central)
  8. Romidepsin (FK228) combined with cisplatin stimulates DNA damage-induced cell death in ovarian cancer. Wilson AJ, Lalani AS, Wass E, Saskowski J, Khabele D (2012) Gynecol Oncol 127(3): 579-86
    › Primary publication · 23010348 (PubMed) · PMC3541411 (PubMed Central)
  9. Low ascorbic acid and increased oxidative stress in gulo(-/-) mice during development. Harrison FE, Meredith ME, Dawes SM, Saskowski JL, May JM (2010) Brain Res : 143-52
    › Primary publication · 20599829 (PubMed) · PMC2914834 (PubMed Central)
  10. Multiple actions of stem cell factor in neural crest cell differentiation in vitro. Langtimm-Sedlak CJ, Schroeder B, Saskowski JL, Carnahan JF, Sieber-Blum M (1996) Dev Biol 174(2): 345-59
    › Primary publication · 8631506 (PubMed)